Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6

Abstract Background Cardiovascular outcome trials (CVOTs) are conducted on a background of standard of care including metformin. These analyses sought to determine whether the cardiovascular (CV) effects of semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1RAs) vary according to...

Full description

Bibliographic Details
Main Authors: Mansoor Husain, Agostino Consoli, Alessandra De Remigis, Anna Sina Pettersson Meyer, Søren Rasmussen, Stephen Bain
Format: Article
Language:English
Published: BMC 2022-04-01
Series:Cardiovascular Diabetology
Subjects:
Semaglutide
SUSTAIN 6
PIONEER 6
Major adverse cardiovascular event
Cardiovascular outcome trial
Metformin
Online Access:https://doi.org/10.1186/s12933-022-01489-6

Internet

https://doi.org/10.1186/s12933-022-01489-6

Similar Items